Selinexor (ATG-010) is a first-in-class Selective Inhibitor of Nuclear Export (SINE) compound, being evaluated in multiple late-stage clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Selinexor has been studied in over 60 clinical trials in over 10 cancer types, with more than 3,100 patients treated. On July 3rd 2019, U.S. FDA granted accelerated approval to XPOVIO (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM).
SINE compounds inhibit nuclear export through covalent binding to cysteine 528 (Cys528) in the cargo-binding pocket of Exportin 1 (XPO1/CRM1) and promote cancer cell death through apoptosis. The XPO1 inhibitors block the nuclear export of tumor suppressor proteins and other growth regulatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity through apoptosis.
We are in partnership with Karyopharm Therapeutics for clinical development, manufacturing and commercialization of selinexor in mainland China and Macau. Antengene is conducting multiple registrational studies of selinexor in China.
Any medical or scientific information provided in this media is intended only for general educational purposes for a medical research study. It provides only general information about the investigational drug Selinexor (KPT 330), and the clinical trial in general. The information provided in this movie is not a replacement for medical evaluation, advice, diagnosis, or treatment. This information is not intended to substitute for physician’s expertise about the appropriateness of a medical research trial for any given individual. Any medical or treatment decisions should be made in consultation with your qualified healthcare provider.